1. A novel biomarker to predict DNA-Repair-inhibitor response in stage I-III high risk breast cancer patients. (November 2022) Authors: Barcaru, A.; Kuilman, M.M.; Wolf, D.; Yau, C.; Choy, E.B.M.; Audeh, W.M.; Brown-Swigart, L.; Hirst, G.L.; Symmans, F.W.; Liu, M.C.; Nanda, R.; Esserman, L.J.; van 't Veer, L.J.; Glas, A.M.; Mittempergher, L. Journal: European journal of cancer Issue: Volume 175(2022)Supplement 1 Page Start: S79 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. An expanded 29-gene HER2 signature robustly identifies genomic HER2-Type early-stage breast tumors. (November 2022) Authors: Ellappalayam, A.; Barcaru, A.; Kuilman, M.M.; Bhaskaran, R.; Audeh, W.M.; Mittempergher, L.; Glas, A.M. Journal: European journal of cancer Issue: Volume 175(2022)Supplement 1 Page Start: S78 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗